Kymriah

Tisagenlecleucel, the active ingredient in Kymriah, is a CAR‑T cell therapy presented as a cellular therapy (autologous T‑cell infusion) for intravenous use. It treats B‑cell acute lymphoblastic leukemia in patients up to 25 years of age and relapsed or refractory large B‑cell lymphoma in adults.

GNH USA supplies Kymriah as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets.

Kymriah is a CAR‑T cell therapy that targets CD19‑positive B‑cell malignancies. - B‑cell acute lymphoblastic leukemia (ALL) in patients ≤25 years: induces remission in relapsed or refractory disease. - Relapsed or refractory large B‑cell lymphoma in adults: achieves durable responses after failure of standard therapies. - CD19‑positive B‑cell malignancies: provides targeted cellular immunotherapy aimed at eliminating malignant B cells.

Kymriah may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cytokine release syndrome (CRS) - B‑cell aplasia - Fever - Fatigue

Serious or Rare Side Effects: - Immune effector cell‑associated neurotoxicity syndrome (ICANS) - Severe infections, including opportunistic pathogens - Prolonged cytopenias - Tumor lysis syndrome

Prior to and after administration of Kymriah, several precautions should be observed to minimize risks. - Patient selection: confirm CD19‑positive disease and meet eligibility criteria. - Monitoring: closely observe for cytokine release syndrome and neurotoxicity during the first weeks post‑infusion. - Infection risk: implement prophylactic antimicrobial measures and monitor for signs of infection. - Vaccination: avoid live vaccines before and for a defined period after therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kymriah’s cellular nature can interact with other therapies, requiring careful management.

Major Interactions (Avoid): - High‑dose corticosteroids administered before infusion: may impair T‑cell expansion and reduce efficacy. - Live vaccines given concurrently or shortly after infusion: increased risk of severe infection.

Moderate Interactions (Monitor Closely): - Concurrent chemotherapy or immunosuppressive agents: may affect lymphocyte collection and product potency. - Anticoagulants: may increase risk of infusion‑related bleeding complications. - Antimicrobial prophylaxis agents: adjust dosing as needed to avoid overlapping toxicities.